Access Industries-backed Acelyrin filed to go public while Lockheed Martin took part in Orbit Fab’s $28.5m series A round.
Public markets
Acelyrin, a US-based inflammatory disorder drug developer backed by industrial conglomerate Access Industries, filed to raise $100m in an initial public offering on the Nasdaq Global Market. It has received a total of $408m in venture funding, and the corporate’s Access Biotechnology unit owns a 3.9% stake having led a $300m series C round in September 2022.
CytoMed Therapeutics, a Singapore-based cancer…
